NIH reports promising data on remdesivir for aiding COVID-19 recovery
A trial sponsored by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases provided preliminary indications that hospitalized patients with advanced COVID-19 and lung involvement who received remdesivir recovered faster than similar patients who received a placebo.
Remdesivir is an investigational, broad-spectrum antiviral treatment administered via daily infusion for 10 days.
The randomized, controlled trial, which involved more than 1,000 patients from multiple sites around the world, found that patients who received remdesivir had a 31% faster recovery time, compare with those who received a placebo — 11 days for patients treated with remdesivir, compared with 15 days for those in the control group.
Related News Articles
Headline
The Food and Drug Administration yesterday announced that Olympus issued a global recall of its ViziShot 2 FLEX needles manufactured prior to May 12 following…
Headline
The Advisory Committee on Immunization Practices Sept. 19 recommended that patients should consult their health care provider if they want to receive a COVID-…
Headline
The Department of Health and Human Services Sept. 18 announced it will take new actions to help improve care for individuals with long COVID. They include a…
Headline
The Food and Drug Administration has identified a Class I recall for Mo-Vis BVBA R-net Joysticks due to a firmware error that causes the wheelchair to ignore…
Headline
The Centers for Disease Control and Prevention is predicting a similar combined number of peak hospitalizations from COVID-19, the flu and respiratory…
Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…